Home  /  Resource Library  /  Umbralisib and ublituximab combination is superior to current standard of care for patients with untreated, relapsed, or refractory CLL

Umbralisib and ublituximab combination is superior to current standard of care for patients with untreated, relapsed, or refractory CLL

ASH 2020: Results of a phase III study examining umbralisib combined with ublituximab for first line treatment of CLL.